Kimberly Brumfield
Family · Gallipolis, OHNPI 1972992196
Payments from drug & device makers
Across 213 payments — averaging $18.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- Otsuka America Pharmaceutical, Inc.$835
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$653
- Indivior Inc.$436
- Alkermes, Inc.$180
- Teva Pharmaceuticals USA, Inc.$159
- plus $543 from 6 others
What the payments were for
- Speaking & faculty fees$56414%
- Food & beverage$3,46786%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 93 | $1,224 |
| Otsuka America Pharmaceutical, Inc. | 9 | $835 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 55 | $653 |
| Indivior Inc. | 22 | $436 |
| Alkermes, Inc. | 8 | $180 |
| Teva Pharmaceuticals USA, Inc. | 3 | $159 |
| Braeburn Inc. | 7 | $126 |
| Acadia Pharmaceuticals Inc | 4 | $107 |
| Sun Pharmaceutical Industries Inc. | 1 | $88 |
| Vanda Pharmaceuticals Inc. | 4 | $84 |
| Johnson & Johnson | 4 | $79 |
| Lundbeck LLC | 3 | $60 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- REXULTI$714
- Austedo XR$125
- VRAYLAR$121
How this compares
$4,031 in reported general payments places this provider in the 90th percentile of 6,812 family providers in Ohio.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| SublocadeBuprenorphine | 16 | $30,457 |
| VraylarCariprazine Hcl | 14 | $19,230 |
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 55 | $2,164 |
| Methenamine Hippurate | 19 | $692 |
| Buspirone Hcl | 40 | $344 |
| Trazodone Hcl | 26 | $199 |
| Tamsulosin Hcl | 22 | $175 |
| Hydroxyzine Hcl | 14 | $159 |
| Tizanidine Hcl | 18 | $117 |
| Metoprolol Succinate | 19 | $113 |
| Memantine Hcl | 16 | $105 |
| Potassium Chloride | 19 | $99 |
| Fluticasone Propionate | 11 | $94 |
| Levothyroxine Sodium | 16 | $84 |
| Oxybutynin Chloride | 11 | $82 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Indivior Inc.Sublocade | $436 | $30,45716 claims |
| AbbVieVraylar | $1,224 | $19,23014 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 6,812 family providers in Ohio.
Other family in Gallipolis
- Suzanna DuncanGallipolis$45K
- Kristin BierhupGallipolis$18K
- Eileen FauldsLewis Center$991K
- Leigh Ann PanschDayton$670K
- Natalie BelliniMayfield Heights$582K
- Kaitlyn LovettMontgomery$286K
- Amy RossDayton$281K
- Renee OttSandusky$179K
- Megan MillerSpringfield$156K
- George KnightCincinnati$130K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.